GSK has entered into an agreement to acquire Canadian biotech company 35Pharma for $950 million in cash.[1][2] 35Pharma specializes in the development of innovative protein-based therapies.[1][2] The acquisition includes the drug HS235, which is in an advanced stage of development and has completed phase 1 clinical trials.[1] HS235 has potential as a first-in-class drug for the treatment of pulmonary hypertension, including pulmonary arterial hypertension and pulmonary hypertension due to heart failure with preserved ejection fraction.[1][2] Studies of HS235 in pulmonary hypertension will begin soon.[1] The transaction is subject to standard conditions, including regulatory approvals in the US and Canada.[1] Tony Wood, Chief Scientific Officer at GSK, said that HS235 offers a distinct bleeding risk reduction profile and possible metabolic benefits for patients with pulmonary hypertension.[1] Forecasts suggest that the global market for pulmonary hypertension therapies will reach $18 billion by 2032.[2]